Partner Therapeutics Announces Publication of Two Studies Demonstrating Leukine® Improves Survival in Acute Radiation Syndrome (ARS)
- Studies Showed Statistically Significant Improvements in Survival in Subjects Treated with Leukine Starting 48 Hours After Acute, High Dose Radiation Exposure without Need for Blood Transfusions or Other Forms of Intensive Supportive Care
- Leukine Administration Starting 48, 72, 96 and 120 Hours after Lethal Radiation Exposure:
- Enhanced Recovery of Platelets, Lymphocytes, Neutrophils and Reticulocytes
- Reduced Frequency, Severity and Duration of Infection, Septicemia and Hemorrhage1
- Studies Provided the Basis for FDA Approval of Leukine for Treatment of Myelosuppression and Hematopoietic Damage and Dysfunction Resulting from ARS